Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

Merck said it plans to make the drug available in the U.S. ahead of the upcoming RSV season. Enflonsia joins a growing arsenal of tools to prevent RSV in infants. Another option, the monoclonal ...